Nombre del producto:(2-Acetyl-4-methylpentyl)trimethylammonium Iodide

IUPAC Name:trimethyl[2-(2-methylpropyl)-3-oxobutyl]azanium iodide

CAS:1069-62-1
Fórmula molecular:C11H24INO
Pureza:95%+
Número de catálogo:CM414743
Peso molecular:313.22

Unidad de embalaje Stock disponible Precio($) Cantidad
CM414743-1g in stock ƴȖ
CM414743-5g in stock ȤȅŸ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1069-62-1
Fórmula molecular:C11H24INO
Punto de fusión:-
Código de sonrisas:[I-].CC(C)CC(C[N+](C)(C)C)C(C)=O
Densidad:
Número de catálogo:CM414743
Peso molecular:313.22
Punto de ebullición:
Nº Mdl:MFCD28143141
Almacenamiento:

Column Infos

Valbenazine
Neurocrine Biosciences announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (Valbenazine) capsules when used for the long-term treatment of adults with chorea associated with Huntington's disease (HD). Interim data suggest one-capsule, once-daily INGREZZA improved chorea at the first evaluation at Week 2 with sustained efficacy through Week 50. INGREZZA® (Valbenazine) is the only one-capsule, once-daily selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by FDA for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products